Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai on Track towards Lecanemab PIII Readout by Sept.-End, Japan/US/EU Filing by March 2023
August 8, 2022
- Kyowa Kirin Books 12.3% Growth in H1 on Global Portfolios, 9.8 Billion Yen FX Gain
August 5, 2022
- Moderna Eyes mRNA Plant in Japan, but Multi-Year Purchase Pact a Must: Local President
August 5, 2022
- Shionogi Nabs Japan Commercial Rights to Grunenthal’s Osteoarthritis Drug
August 5, 2022
- Izcargo Fails to Win Approval in Brazil; JCR Aims for Refiling
August 4, 2022
- Trulicity Sales Alliance Deal to Expire by 2022-End: Lilly Japan/Sumitomo
August 4, 2022
- Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
- Mitsubishi Tanabe’s Q1 Sales Rise 2.9% on Growth in Japan
August 4, 2022
- Lenvima/Keytruda Combo Fails in PIII HCC Trial
August 4, 2022
- Japan Pharma Market to Reach 9.4 Trillion Yen in 2030: Fuji Keizai
August 4, 2022
- AstraZeneca, Tech Nation Link Arms to Help Startups Foray into Japan, UK
August 3, 2022
- Astellas Taps Ex-AstraZeneca Exec Taniguchi as New CMO
August 3, 2022
- Sawai Grabs Japan Rights to CureApp’s NASH Therapeutic App
August 3, 2022
- Sosei, AbbVie Expand Collaboration into Neurological Arena
August 3, 2022
- Ayumi to Boost Calonal Output to 2.88 Billion Tablets, Still August Shortage Likely
August 3, 2022
- Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
- Nipro to Temporarily Halt Some Cefazolin Supplies, Competitors Respond with Shipment Curbs
August 2, 2022
- Ono Logs Two-Digit Growth in Q1 Earnings on Opdivo
August 2, 2022
- Astellas’ Earnings Hit by FX as Cost Rate Worsens on Overseas Inventories
August 2, 2022
- Shionogi’s Q1 Sales Up 4.2% on HIV Franchise, FX
August 2, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…